The Coagulation Unit was established as part of the Department of Hematology, paralleling the development of the field itself over the years. Previously, coagulation specialists focused on treating a small group of patients in a population suffering from congenital bleeding disorders (hemophilia, von willebrand, thrombasthenia, glanzman, etc.). Recently, there has a been a shift of focus to include prevention and prenatal diagnosis of these diseases.
The development of hemaphilia treatment has led to the introduction of advanced development and implementation of new drugs, not only for these diseases but for surgical, trauma and maternity patients as well.
Congenital bleeding diseases and syndromes characterized by an increasing tendency to coagulate are now one of the most common causes of morbidity and mortality in the population. Identifying the factors responsible for hypercoagulable states will enable policy planning for treatment methods and recognizing other family members carrying the disease.
New anti-thrombotic drugs that have appeared on the market in recent years have dramatically changed the therapeutic approach in patients with venous thromboses and heart patients undergoing invasive procedures. The activity of the Coagulation Unit is quite extensive and includes clinics at Hadassah Ein Kerem and Mount Scopus (in the Hematology and Ob/Gyn/Maternity departments), counseling to inpatient wards in the hospital, anticoagulation clinics in the healthcare branches.
The Coagulation Unit operates two areas of research - basic research and clinical research. The basic research concentrates on platelet involvement in the process of angiogenesis (including situations of cancer and ischemic conditions), and mentors research students and doctors. The main clinical study concentrates on platelet function in various situations (including thalassemia, cardiac surgery, sickle cell anemia, intensive care, fractured neck of the femur, liver surgery and heart disease). The study was done in collaboration with various departments in the hospital and in collaboration with other researchers in the country and abroad. The research applies the CPA method among others, which was developed in the Coagulation laboratory and is soon to enter clinical use. Students and physicians are being accepted to do their final projects and basic sciences theses in this area too.
The Unit also participates in several local and multi-center clinical studies on subjects such as innovative treatments and various anti-thrombotic protocols.
Prof. Varon David is the director of the Coagulation Unit at the Sharett Institute,
Professor Varon also runs a clinic in the Maccabi Healthcare Services Community Health Center of Hadassah in the Kiryat HaYovel neighborhood of Jerusalem. To schedule an appointment, please call 02-6419111.
In addition, congenital coagulation clinics are held in the Women's clinics in Ein Kerem and Mount Scopus.
The Coagulation Unit provides platelet function testing and studies in coagulation models. Specifically, the Coagulation Unit routinely carries out platelet aggregation and bleeding assays. It can provide endothelial cell models, angiogenesis models and models for clot formation. The Coagulation Unit has collaborated with Omrix, BiolineRx and Lilly to provide platelet coagulation and in vivo bleeding testing as well as drug response testing and in vitro and in vivo endothelial and angiogenesis assays. The Unit is also available for consultation and counseling.
The Unit has a cone and platelet analyzer (CPA) and has developed a proprietary assay which employs the CPA to examine platelet aggregation and adhesion under shear. This unique methodology is described in a 2006 publication by Savion and Varon in Pathophysiol Haemost Thromb.
Another proprietary assay developed in the Unit is aspirin response testing.
Laboratory Director - The Director of the Coagulation Unit is Prof. David Varon, M.D., of the Department of Hematology. Prof. Varon has served as Medical Director of Matis and consultant to Omrix and BiolineRx. Under his direction the Coagulation Unit has carried out collaborations with Omrix, BiolineRx and Lilly.